Development of new prolactin analogs acting as pure prolactin receptor antagonists
- PMID: 14703018
- DOI: 10.1023/b:pitu.0000004799.41035.9f
Development of new prolactin analogs acting as pure prolactin receptor antagonists
Abstract
Prolactin (PRL) promotes tumor growth, as recently highlighted by the spontaneous appearance of prostate hyperplasia and mammary neoplasia in PRL transgenic mice. Increasing experimental evidence argues for the involvement of autocrine PRL in this process. Human (h)PRL receptor antagonists have been developed to counteract these undesired proliferative actions of PRL. However, all PRL receptor antagonists obtained to date exhibit partial agonism, limiting their therapeutic use as full antagonists. This is the case for the first generation antagonists (the prototype of which is G129R-hPRL) that we developed ten years ago, which display antagonistic activity in some, but not all in vitro bioassays, and fail to inhibit PRL activity in transgenic mice expressing this analog. We recently developed new human PRL antagonists devoid of agonistic properties, and therefore able to act as pure antagonists. This was demonstrated using several in vitro bioassays, including assays able to detect extremely low levels of receptor activation. These new compounds also act as pure antagonists in vivo, as demonstrated by their ability to competitively inhibit PRL-triggered signaling cascades in various target tissues (liver, mammary gland and prostate). Finally, using transgenic mice specifically expressing PRL in the prostate, which have constitutively activated signaling cascades and prostate hyperplasia, these new PRL analogs are able to completely revert PRL-activated events to basal levels. These second generation antagonists are good candidates to be used as inhibitors of the growth-promoting actions of hPRL.
Similar articles
-
Development of pure prolactin receptor antagonists.J Biol Chem. 2003 Sep 19;278(38):35988-99. doi: 10.1074/jbc.M305687200. Epub 2003 Jun 24. J Biol Chem. 2003. PMID: 12824168
-
Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.Oncogene. 2000 Sep 28;19(41):4695-705. doi: 10.1038/sj.onc.1203846. Oncogene. 2000. PMID: 11032019
-
Development and potential clinical uses of human prolactin receptor antagonists.Endocr Rev. 2005 May;26(3):400-22. doi: 10.1210/er.2004-0016. Epub 2005 Apr 6. Endocr Rev. 2005. PMID: 15814850 Review.
-
Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay.J Biol Chem. 1996 Jul 12;271(28):16573-9. doi: 10.1074/jbc.271.28.16573. J Biol Chem. 1996. PMID: 8663214
-
Use of prolactin receptor antagonist to better understand prolactin regulation of pituitary homeostasis.Neuroendocrinology. 2013;98(3):171-9. doi: 10.1159/000354701. Epub 2013 Sep 19. Neuroendocrinology. 2013. PMID: 23969780 Review.
Cited by
-
Prolactin modulates TRPV1 in female rat trigeminal sensory neurons.J Neurosci. 2006 Aug 2;26(31):8126-36. doi: 10.1523/JNEUROSCI.0793-06.2006. J Neurosci. 2006. PMID: 16885226 Free PMC article.
-
Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells.Endocrinology. 2009 Apr;150(4):1782-90. doi: 10.1210/en.2008-1057. Epub 2008 Nov 20. Endocrinology. 2009. PMID: 19022890 Free PMC article.
-
Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders.MAbs. 2023 Jan-Dec;15(1):2254676. doi: 10.1080/19420862.2023.2254676. MAbs. 2023. PMID: 37698877 Free PMC article.
-
From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):147-56. doi: 10.1007/s10911-008-9074-8. Epub 2008 Feb 2. J Mammary Gland Biol Neoplasia. 2008. PMID: 18246318 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases